M&A Deal Summary |
|
|---|---|
| Date | 2022-12-02 |
| Target | Bioassay |
| Sector | Life Science |
| Buyer(s) | Reaction Biology |
| Deal Type | Add-on Acquisition |
| Advisor(s) | ACXIT Capital (Financial) Goodwin Procter (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2001 |
| Sector | Life Science |
| Employees | 130 |
Reaction Biology is a contract research organization (CRO) that provides a full suite of drug discovery services to over 1,800 biopharmaceutical customers worldwide. Reaction's capabilities include functional biochemical assays, compound screening, a wide range of mechanistic and biophysical studies, and an extensive array of cell-based assays. Reaction Biology was founded in 2001 and is based in Malvern, Pennsylvania.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 1 of 1 |
| Country: Germany M&A | 1 of 1 |
| Year: 2022 M&A | 1 of 1 |
